Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Jacobs

Showing results (31-40 of 131) with videos related to

Pageof 14
Sort By:
The American Journal of Medicine|February 27, 2004
Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severityDonald D Sin, Kamran Golmohammadi, Philip Jacobs
Pharmacoeconomics - Open|February 15, 2018
Authors' Reply to Holko: "Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A Review"Ilke Akpinar, Philip Jacobs, Dat T Tran
Psychiatric Services (Washington, D.C.)|October 5, 2010
Sources of revenue for nonprofit mental health and addictions organizations in CanadaCarissa Escober-Doran, Philip Jacobs, Carolyn Dewa
Expert Review of Vaccines|October 29, 2013
Vaccine development costs: a reviewArianna Waye, Philip Jacobs, Anthony B Schryvers
Canadian Family Physician Medecin De Famille Canadien|November 13, 2021
Can you afford to keep practising? Family medicine finances transformed by COVID-19 in AlbertaPhilip Jacobs, Neil R Bell, Douglas Woudstra
Canadian Respiratory Journal|July 9, 2005
Private costs of patients hospitalized with community-acquired pneumoniaPhilip Jacobs, Thomas J Marrie, Peter Calder
Pharmacoeconomics - Open|February 15, 2018
Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A ReviewIlke Akpinar, Philip Jacobs, Tien Dat Tran
Lung|November 6, 2004
Economic evaluation of a community-based pulmonary rehabilitation program for chronic obstructive pulmonary diseaseKamran Golmohammadi, Philip Jacobs, Don D Sin
The Journal of Rheumatology. Supplement|November 3, 2011
Socioeconomic burden of immune-mediated inflammatory diseases--focusing on work productivity and disabilityPhilip Jacobs, Robert Bissonnette, Lyn C Guenther
Obesity (Silver Spring, Md.)|July 21, 2006
Population-based analysis of obesity and workforce participationScott Klarenbach, Raj Padwal, Anderson Chuck, et al.
Pageof 14

Showing results (31-40 of 131) with videos related to

Sort By:
Pageof 14
The American Journal of Medicine|February 27, 2004
Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severityDonald D Sin, Kamran Golmohammadi, Philip Jacobs
Pharmacoeconomics - Open|February 15, 2018
Authors' Reply to Holko: "Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A Review"Ilke Akpinar, Philip Jacobs, Dat T Tran
Psychiatric Services (Washington, D.C.)|October 5, 2010
Sources of revenue for nonprofit mental health and addictions organizations in CanadaCarissa Escober-Doran, Philip Jacobs, Carolyn Dewa
Expert Review of Vaccines|October 29, 2013
Vaccine development costs: a reviewArianna Waye, Philip Jacobs, Anthony B Schryvers
Canadian Family Physician Medecin De Famille Canadien|November 13, 2021
Can you afford to keep practising? Family medicine finances transformed by COVID-19 in AlbertaPhilip Jacobs, Neil R Bell, Douglas Woudstra
Canadian Respiratory Journal|July 9, 2005
Private costs of patients hospitalized with community-acquired pneumoniaPhilip Jacobs, Thomas J Marrie, Peter Calder
Pharmacoeconomics - Open|February 15, 2018
Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A ReviewIlke Akpinar, Philip Jacobs, Tien Dat Tran
Lung|November 6, 2004
Economic evaluation of a community-based pulmonary rehabilitation program for chronic obstructive pulmonary diseaseKamran Golmohammadi, Philip Jacobs, Don D Sin
The Journal of Rheumatology. Supplement|November 3, 2011
Socioeconomic burden of immune-mediated inflammatory diseases--focusing on work productivity and disabilityPhilip Jacobs, Robert Bissonnette, Lyn C Guenther
Obesity (Silver Spring, Md.)|July 21, 2006
Population-based analysis of obesity and workforce participationScott Klarenbach, Raj Padwal, Anderson Chuck, et al.
Pageof 14